Editor’s Note: Lyme disease has been strongly associated with Alzheimer’s in recent years and is believed to be one of its causes. Therefore, based on the results of this article, it stands to reason that probiotic therapy may also have a beneficial effect upon cognition, depression and other neurological symptoms in those with Lyme.
Subscribe to the World's Most Popular Newsletter (it's free!)
To read the entire article for free, click here.
Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels
Gut microbiota has a proven role in regulating multiple neuro-chemical pathways through the highly interconnected gut-brain axis. Oral bacteriotherapy thus has potential in the treatment of central nervous system-related pathologies, such as Alzheimer's disease (AD). Current AD treatments aim to prevent onset, delay progression and ameliorate symptoms.
In this work, 3xTg-AD mice in the early stage of AD were treated with SLAB51 probiotic formulation, thereby affecting the composition of gut microbiota and its metabolites. This influenced plasma concentration of inflammatory cytokines and key metabolic hormones considered therapeutic targets in neurodegeneration.
Treated mice showed partial restoration of two impaired neuronal proteolytic pathways (the ubiquitin proteasome system and autophagy). Their cognitive decline was decreased compared with controls, due to a reduction in brain damage and reduced accumulation of amyloid beta aggregates.
Collectively, our results clearly prove that modulation of the microbiota induces positive effects on neuronal pathways that are able to slow down the progression of Alzheimer's disease.
Source: By Bonfili L1, Cecarini V2, Berardi S2, Scarpona S2, Suchodolski JS3, Nasuti C4, Fiorini D5, Boarelli MC5, Rossi G2, Eleuteri AM2. Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017 May 25;7(1):2426. doi: 10.1038/s41598-017-02587-2.